Living Medical
Textbook
From Projects In Knowledge
Osteoporosis
Fracture Prevention and Therapeutic Management Edition
Table of Contents
|
CME/CE Information
|
Technical Requirements
|
Login
Chapter 1
Overview of Osteoporosis
Last Reviewed: May 20, 2010
Chapter 2
Identifying Patients at Risk for Osteoporosis and Fractures
Last Reviewed: May 20, 2010
Chapter 3
Assessment of Fracture Risk Using FRAX
®
Last Reviewed: May 20, 2010
–
Assessing Fracture Risk in Clinical Practice
–
What is FRAX?
–
Using FRAX in Clinical Practice
–
Treatment Decisions Using FRAX
–
Limitations and Caveats
–
References
Chapter 4
Treatment of Osteoporosis
Last Reviewed: May 20, 2010
Chapter 5
Management of the Postfracture Patient
Last Reviewed: May 20, 2010
Chapter 6
Monitoring
Last Reviewed: May 20, 2010
/1892/images/PIKEduInit.gif [NO]
This activity is supported by an educational donation provided by
Amgen
.
/1892/iPhoneAd/1892iPhoneAd.gif [NO]
Osteoporosis News powered by
This CME program will include a brief pretest. Please start now by answering these 4 questions:
1.
Which of the following is not an output of FRAX?
*
10-year probability of vertebral fracture
10-year probability of major osteoporotic fracture
10-year probability of hip fracture
All of the above are outputs of FRAX
2.
Which of the following risk thresholds calculated by FRAX (in a postmenopausal woman) is an indication for treatment according to the National Osteoporosis Foundation?
*
10-year risk of major osteoporotic fracture of 18%
10-year risk of hip fracture of 4%
10-year risk of major osteoporotic fracture of 15%
10-year risk of hip fracture of 2%
3.
FRAX may underestimate fracture risk in a woman who:
*
Smokes two packs of cigarettes per day.
Has a prevalent clinical vertebral fracture.
Uses inhaled steroids to treat her asthma.
Drinks one glass of wine each night with dinner.
4.
How often do you
currently use
each of the following clinical practice strategies?
*
Always
Very Often
Sometimes
Not Very Often
Never
N/A
Utilize FRAX
®
for postmenopausal women or men aged 50 years and over with osteopenia to estimate 10-year fracture risk
Use National Osteoporosis treatment guidelines to make treatment decisions based on FRAX results in postmenopausal women or men aged 50 years and over with osteopenia
Complete the FRAX questionnaire with full understanding of the data requested
Use the FRAX questionnaire and results as a basis for patient education regarding fracture risk reduction by nonpharmacologic therapy or bone-active agents
Use clinical judgment when completing the FRAX questionnaire and interpreting FRAX results